US EditionEli Lilly's experimental Mounjaro pill showcases promising weight loss results
MARION COUNTY, INDIANA, AUG 7 – The oral GLP-1 pill orforglipron led to an average 12% weight loss in trials involving over 3,000 adults with obesity or overweight, offering a convenient alternative to injections.
- On Aug. 7, Eli Lilly revealed that its experimental orforglipron pill helped people lose an average 12% of body weight after 72 weeks in a phase three trial.
- Amid barriers posed by injectable GLP-1 therapies, Eli Lilly pursued an oral option because for many, injections have stopped them from trying these medications, Eli Lilly said.
- The trial enrolled 3,127 adults, with 5 to 10 percent discontinuing due to gastrointestinal issues, and participants lost 7.8% to 12.4% of body weight, Eli Lilly reported.
- In an Aug. 7 earnings call, CEO David Ricks said Eli Lilly plans to submit orforglipron to the FDA by year's end and hopes it will be available this year, though investors expressed concerns about efficacy.
- With about 8 million Americans on obesity medications and 170 million eligible, pills can be produced at scale, broadening access to treatment, Eli Lilly's Custer said.
14 Articles
14 Articles
Wegovy, Ozempic and others are suspected promises of healing for people with obesity, but all syringes. The US pharmaceutical company Eli Lilly wants to apply for the approval of a weight loss tablet by the end of the year. Experts do not see a basic problem solved.
Will a new pill beat out other weight-loss medications like Ozempic and Mounjaro?
Eli Lilly’s weight-loss pill, orforglipron, shows promising results in trials, offering a needle-free alternative to injectables like Ozempic and Mounjaro. In a major study, people who took the drug lost more than 12 per cent of their body weight. Is it better than popular injectables?
Eli Lilly's experimental Mounjaro pill showcases promising weight loss results
A popular diabetes and weight loss drug could be on the horizon in pill form as drugmaker Eli Lilly released results of an experimental GLP-1 phase three trial.Mounjaro, which is marketed to treat Type 2 diabetes, and Zepbound, which is intended to treat obesity, are used as injectable medications. But they could soon be administered in pill form, Eli Lilly said.The once-daily pill helped people lower their weight by an average of 12% after 72 w…
Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says - ABC Columbia
(CNN)– Eli Lilly hopes to be the first drugmaker to offer an effective GLP-1 in pill form to treat obesity. The company already makes the injectable GLP-1 drugs Zepbound, Mounjaro and Trulicity. Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an average of 12% after 72 weeks. The pill was also tied t…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
